

REGENERON PHARMACEUTICALS INC

Form 4

May 03, 2013

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
SCHLEIFER LEONARD S

(Last) (First) (Middle)

**777 OLD SAW MILL RIVER
ROAD**

(Street)

TARRYTOWN, NY 10591

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
**REGENERON
PHARMACEUTICALS INC
[REGN]**

3. Date of Earliest Transaction
(Month/Day/Year)
05/01/2013

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☐ Director ☐ 10% Owner
☒ Officer (give title below) ☐ Other (specify below)
President & CEO

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2013		S(1)		20,400	D	\$ 225.01 (2)
Common Stock	05/01/2013		S(1)		850	D	\$ 226.26 (3)
Common Stock	05/01/2013		S(1)		500	D	\$ 227.4
Common	05/01/2013		S(1)		622	D	\$ 119,715

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Stock					228.04		
					<u>(4)</u>		
Common Stock	05/01/2013	<u>S(1)</u>	5,300	D	\$ 231.18 <u>(5)</u>	114,415	D
Common Stock	05/01/2013	<u>S(1)</u>	700	D	\$ 232.18 <u>(6)</u>	113,715	D
Common Stock	05/01/2013	<u>S(1)</u>	5,000	D	\$ 233.34	108,715	D
Common Stock	05/01/2013	<u>S(1)</u>	400	D	\$ 235.75 <u>(7)</u>	108,315	D
Common Stock	05/01/2013	<u>S(1)</u>	3,327	D	\$ 236.47 <u>(8)</u>	104,988	D
Common Stock	05/01/2013	<u>S(1)</u>	2,300	D	\$ 237.31 <u>(9)</u>	102,688	D
Common Stock	05/01/2013	<u>S(1)</u>	3,089	D	\$ 238.65 <u>(10)</u>	99,599	D
Common Stock	05/01/2013	<u>S(1)</u>	4,087	D	\$ 239.68 <u>(11)</u>	95,512	D
Common Stock	05/01/2013	<u>S(1)</u>	7,295	D	\$ 240.44 <u>(12)</u>	88,217	D
Common Stock	05/01/2013	<u>S(1)</u>	3,350	D	\$ 241.25 <u>(13)</u>	84,867	D
Common Stock	05/01/2013	<u>S(1)</u>	4,695	D	\$ 242.54 <u>(14)</u>	80,172	D
Common Stock	05/01/2013	<u>S(1)</u>	11,938	D	\$ 243.41 <u>(15)</u>	68,234	D
Common Stock	05/01/2013	<u>S(1)</u>	9,814	D	\$ 244.49 <u>(16)</u>	58,420	D
Common Stock	05/01/2013	<u>S(1)</u>	5,383	D	\$ 245.55 <u>(17)</u>	53,037	D

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock	05/01/2013	<u>S(1)</u>	8,700	D	\$ 246.13 (18)	44,337	D	
Common Stock	05/01/2013	<u>S(1)</u>	450	D	\$ 247.32 (19)	43,887	D	
Common Stock	05/01/2013	<u>S(1)</u>	900	D	\$ 248.72 (20)	42,987	D	
Common Stock	05/01/2013	<u>S(1)</u>	600	D	\$ 249.45 (21)	42,387	D	
Common Stock	05/01/2013	<u>S(1)</u>	300	D	\$ 250.06	42,087	D	
Common Stock						5,618	I	By 401(k) Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Transaction (Instr. 6)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address

Relationships

Director	10% Owner	Officer	Other
X		President & CEO	

SCHLEIFER LEONARD S
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591

Signatures

/s/**Leonard S.
Schleifer

05/03/2013

__Signature of Reporting
Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Represents volume-weighted average price of sales of 20,400 shares of Company stock on May 1, 2013 at prices ranging from \$225.00 to \$225.24. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.

(3) Represents volume-weighted average price of sales of 850 shares of Company stock on May 1, 2013 at prices ranging from \$226.00 to \$226.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.

(4) Represents volume-weighted average price of sales of 622 shares of Company stock on May 1, 2013 at prices ranging from \$228.00 to \$228.20. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.

(5) Represents volume-weighted average price of sales of 5,300 shares of Company stock on May 1, 2013 at prices ranging from \$231.04 to \$231.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.

(6) Represents volume-weighted average price of sales of 700 shares of Company stock on May 1, 2013 at prices ranging from \$232.17 to \$232.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.

(7) Represents volume-weighted average price of sales of 400 shares of Company stock on May 1, 2013 at prices ranging from \$235.64 to \$235.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.

(8) Represents volume-weighted average price of sales of 3,327 shares of Company stock on May 1, 2013 at prices ranging from \$236.17 to \$236.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.

(9) Represents volume-weighted average price of sales of 2,300 shares of Company stock on May 1, 2013 at prices ranging from \$237.08 to \$237.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.

(10) Represents volume-weighted average price of sales of 3,089 shares of Company stock on May 1, 2013 at prices ranging from \$238.22 to \$238.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.

(11) Represents volume-weighted average price of sales of 4,087 shares of Company stock on May 1, 2013 at prices ranging from \$239.04 to \$239.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.

(12) Represents volume-weighted average price of sales of 7,295 shares of Company stock on May 1, 2013 at prices ranging from \$240.00 to \$240.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.

(13) Represents volume-weighted average price of sales of 3,350 shares of Company stock on May 1, 2013 at prices ranging from \$241.02 to \$241.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

- Represents volume-weighted average price of sales of 4,695 shares of Company stock on May 1, 2013 at prices ranging from \$242.14 to
- (14) \$242.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.
- Represents volume-weighted average price of sales of 11,938 shares of Company stock on May 1, 2013 at prices ranging from \$243.00
- (15) to \$243.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.
- Represents volume-weighted average price of sales of 9,814 shares of Company stock on May 1, 2013 at prices ranging from \$244.05 to
- (16) \$244.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.
- Represents volume-weighted average price of sales of 5,383 shares of Company stock on May 1, 2013 at prices ranging from \$245.00 to
- (17) \$245.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.
- Represents volume-weighted average price of sales of 8,700 shares of Company stock on May 1, 2013 at prices ranging from \$246.00 to
- (18) \$246.67. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.
- Represents volume-weighted average price of sales of 450 shares of Company stock on May 1, 2013 at prices ranging from \$247.18 to
- (19) \$247.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.
- Represents volume-weighted average price of sales of 900 shares of Company stock on May 1, 2013 at prices ranging from \$248.60 to
- (20) \$248.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.
- Represents volume-weighted average price of sales of 600 shares of Company stock on May 1, 2013 at prices ranging from \$249.44 to
- (21) \$249.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2013 at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.